Barclays’s Context Therapeutics CNTX Stock Holding History

Barclays’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-167	Closed	-$162	–	5306
2025 Q3	$162	Buy	+167	New	+$135	﹤0.01%	5251

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Barclays's CNTX Position: Q4 2025 in Review

Barclays sold out of Context Therapeutics (CNTX) in Q4 2025, closing a stake of 167 shares — an estimated $162 sold.

Barclays first reported a position in CNTX in Q3 2025 and held it in 1 quarter. The position peaked at $162 in Q3 2025. 42 funds tracked by Wall St. Rank hold CNTX as of Q4 2025.

Barclays reported no remaining Context Therapeutics position as of Q4 2025 after selling out during the quarter.
Barclays sold 167 Context Therapeutics shares in Q4 2025, an estimated $162.
Barclays first reported a position in Context Therapeutics in Q3 2025 and held it in 1 quarter.
Barclays's Context Therapeutics position peaked at $162 in Q3 2025.
42 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.